Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Declines By 31.4%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant decrease in short interest in January. As of January 30th, there was short interest totaling 20,320 shares, a decrease of 31.4% from the January 15th total of 29,614 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average trading volume of 25,094 shares, the days-to-cover ratio is currently 0.8 days. Based on an average trading volume of 25,094 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.2% of the company’s stock are short sold.

Catheter Precision Stock Up 12.6%

VTAK stock traded up $0.16 during trading on Friday, reaching $1.43. 1,150,589 shares of the stock were exchanged, compared to its average volume of 158,135. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. Catheter Precision has a twelve month low of $1.14 and a twelve month high of $15.68. The firm’s 50 day moving average is $2.04 and its 200 day moving average is $2.37.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($26.60) by $24.90. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%.The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $1.20 million. Equities analysts expect that Catheter Precision will post -8.9 EPS for the current fiscal year.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.